Similarly, Sorafenib‘s effectiveness in targeting multiple kinases involved in tumor cell proliferation and angiogenesis is well-documented, with its role in inhibiting the RAF/MEK/ERK pathway contributing to its therapeutic efficacy in cancers such as renal cell carcinoma and hepatocellular carcinoma [64,65,66]. This evidence concerns the gene MAP2K7 and hereditary clear cell renal cell carcinoma.